Skip to main content

Advertisement

SpringerLink
Log in

Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

  • Published:
Journal of NeuroVirology Aims and scope Submit manuscript

Abstract

Viral infections have been appointed as the main component of environmental susceptibility to multiple sclerosis (MS). Interferon beta is an immunomudulatory treatment that is able to modify the natural course of the disease; nonetheless, its mechanism of action in not well established yet. The objectives of the present study were (1) to evaluate the bioavailability of interferon beta through the measurement of the expression of myxovirus resistance protein (MxA), metalloproteinase 9 (MMP-9), and its inhibitor (TIMP-1); (2) to analyze its antiviral efficiency through the measurement of human herpesvirus-6 (HHV-6) prevalence; and (3) to correlate both parameters (bioavailability and antiviral efficiency) with the relapse rate in multiple sclerosis (MS) patients treated with interferon beta. Pairs of blood and serum samples were collected from 54 MS patients during five visits in 1 year: one before the start of the treatment and four during interferon beta treatment. Expression of MxA, MMP-9, and TIMP-1 was analyzed by quatitative real-time polymerase chain reaction (qRT-PCR) and HHV-6 genomes were detected by qPCR. The results showed a correlation between MxA and relapse rate (P = .014). MMP-9/TIMP-1 ratio was increased among the patients with relapses, and decreased among the relapse-free patients, although differences were not statistically significant. Furthermore, our results suggest a possible role for HHV-6 in MS, because 42.8% of patients with viral reactivations experienced at least one relapse versus 22.5% of patients without viral reactivations. Lastly, regarding the antiviral effectiveness of the interferon beta, the HHV-6 prevalence decreased from 58% to 36% in PBMCs and from 18.5% to 12.2% in sera; furthermore, a good correlation with the bioavailability of interferon beta was found, because patients with a decrease in HHV-6 prevalence had higher levels of MxA (P = .046, at the third month).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahlqvist J, Fotheringham J, Akhyani N, Yaoo K, Fogdell Hahn A, Jacobson (2005). Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J NeurVirol 11: 384–394.

    Article  CAS  Google Scholar 

  • Alvarez-Lafuente R, Martín-Estefanía C, De las Heras V, Castrillo C, Cour I, Picazo JJ, Varela de Seijas E, Arroyo R (2002a). Prevalence of herpesvirus DNA in MS patients and healthy blood donnors. Acta Neurol Scand 105: 95–99.

    Article  CAS  PubMed  Google Scholar 

  • Alvarez-Lafuente R, Martín-Estefanía C, De las Heras V, Castrillo C, Picazo JJ, Varela E, Arroyo R (2002b). Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol 59: 929–933.

    Article  PubMed  Google Scholar 

  • Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M (2005). Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 11: 441–446.

    Article  CAS  PubMed  Google Scholar 

  • Cermelli C, Berti R, Soldan SS, Mayne M, D’ambrosia JM, Ludwin SK, Jacobson S (2003). High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 187: 1377–1387.

    Article  CAS  PubMed  Google Scholar 

  • Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, Schad PA, Stewart PM, Nowinski RC, Brown PB, Burmer GC (1995). Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 92: 7440–7444.

    Article  CAS  PubMed  Google Scholar 

  • Chapenko S, Millar A, Nora Z, Logina I, Kukaine R, Murovska M. (2003). Correlation between HHV-6 reactivation and multiple sclerosis disease activity. J Med Virol 69: 111–117.

    Article  PubMed  Google Scholar 

  • Deisenhammer F, Reindl M, Harvey J (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52: 1239–1243.

    CAS  PubMed  Google Scholar 

  • European Study Group on interferon beta-1b in secondary progressive MS (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491–1497.

    Article  Google Scholar 

  • Gilli F, Bertolotto A, Sala A, Hoffman F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RLP, Leppert D (2004). Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β-mediated supp suppression of MMPs. Brain 127: 259–268.

    Article  PubMed  Google Scholar 

  • Gilli F, Sala A, Bancote C, Salacone P, Gallo M., Gaia E, Bertolotto A (2002). Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. J Immunol Methods 262: 187–190.

    Article  CAS  PubMed  Google Scholar 

  • Giovannoni F, Munschauer E 3rd, Deisenhammer F (2002). Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73: 465–469.

    Article  CAS  PubMed  Google Scholar 

  • Hickey WF, Hsu BL, Kimura H (1991). T-lymphocyte entry into the central nervous system. J Neurosci Res 28: 254–260.

    Article  CAS  PubMed  Google Scholar 

  • Higashikata T, Yamagishi M, Sasaki H, Minatoya K, Ogino H, Ishibashi-Ueda H, Hao H, Nagaya N, Tomoike H, Sakamoto A (2004). Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis 177: 353–360.

    Article  CAS  PubMed  Google Scholar 

  • Hong J, Tejada-Simón MV, Rivera VM, Zang YCQ, Zhang JZ (2002). Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult scler 8: 237–242.

    Article  CAS  PubMed  Google Scholar 

  • Hymas W, Stevenson J, Taggart EW, Hillyard D (2005). Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. J Virol Methods 143–150.

  • Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Gininger DG, Wong DT, Schmidt BL (2004). Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 10: 6460–6465.

    Article  CAS  PubMed  Google Scholar 

  • Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K (1999). Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122: 191–197.

    Article  PubMed  Google Scholar 

  • Lepert D, Lindberg RL, Kappos L, Leib SL (2001). Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 36: 249–257.

    Article  Google Scholar 

  • Medeiros M, Sharma VK, Ding R, Yamaji K, Li B, Muthukumar T, Valderde-Rosas S, Hernandez AM, Muñoz R, Suthanthiran M (2003). Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 279: 135–142.

    Article  CAS  PubMed  Google Scholar 

  • Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA (2000). Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology 55: 1569–1572.

    CAS  PubMed  Google Scholar 

  • Opdenakker G, Van den Steen PE, Dubos B, Nelissen I, Van Damme J (2001). Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69: 851–859.

    CAS  PubMed  Google Scholar 

  • Pachner AR, Bertolotto A, Deisenhammer F (2003). Measurement of MxA or protein as a biomarker of IFNβ bioactivity. Neurology 61(Suppl 5): S24-S26.

    CAS  PubMed  Google Scholar 

  • Pachner AR, Dail D, Pak E, Narayan K (2005). The importance of measuring IFN-β antibodies bioactivity: Monitoring in MS patients and the effect of anti-IFN-β antibodies. J Neuroimmunol 166: 180–188.

    Article  CAS  PubMed  Google Scholar 

  • Pachner AR, Narayan K, Price N, Hurd M, Dail D (2003). MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 7: 17–25.

    Article  PubMed  Google Scholar 

  • Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group (2002). Evidence of Interferon Dose-response: European North American Comparative Efficacy, University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS. Neurology 59: 1496–1506.

    CAS  PubMed  Google Scholar 

  • Raine CS, Canella B, Duijvestijn AM, Cross AH (1990). Homing to central nervous system vasculature by antigen-specific lymphocytes.II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 63: 476–89.

    CAS  PubMed  Google Scholar 

  • Rice G (2001). The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 58: 1297–8.

    Article  CAS  PubMed  Google Scholar 

  • Ross C, Clemmesen KM, Svenson M (2000). Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48: 706–712.

    Article  CAS  PubMed  Google Scholar 

  • Rudick RA, Simonian NA, Alam JA (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50: 1266–1272.

    CAS  PubMed  Google Scholar 

  • Sorensen PS, Ross C, Clemmesen KM., Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group (2003). Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184–1191.

    Article  CAS  PubMed  Google Scholar 

  • Suhayl DJ (2002). Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58: S3-S9.

    Google Scholar 

  • Tejada-Simon MV, Zang YCQ, Hong J, Rivera VM, Zhang JZ (2003). Cross-reactivity with myelin basic protein and human-herpesvirus-6 in multiple sclerosis. Ann Neurol 53: 189–97.

    Article  CAS  PubMed  Google Scholar 

  • The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889–894.

    Google Scholar 

  • The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (2005). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277–1285.

    Google Scholar 

  • Waubant, E., Goodkin, D., Bostrom, A., Bacchetti, P., Hietpas, J., Lindberg, R., Leppert, D (2003). IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60: 52–57.

    CAS  PubMed  Google Scholar 

  • Yong VW, Krekoski CA, Forsyth P, Bell R, Edwards DR (1998). Matrix metalloproteases and disease of the CNS. Trends Neurosci 21: 75–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain

    Marta Garcia-Montojo, Virginia De Las Heras, Manuel Bartolome, Rafael Arroyo & Roberto Alvarez-Lafuente

  2. Laboratorio de Investigación 7a Norte, Hospital Clínico San Carlos, C./ Profesor Martín Lagos s/n., 28040, Madrid, Spain

    Roberto Alvarez-Lafuente

Authors
  1. Marta Garcia-Montojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia De Las Heras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Bartolome
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rafael Arroyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Alvarez-Lafuente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Alvarez-Lafuente.

Additional information

This work was supported by the grant FIS no. 03/0589.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garcia-Montojo, M., De Las Heras, V., Bartolome, M. et al. Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients. Journal of NeuroVirology 13, 504–512 (2007). https://doi.org/10.1080/13550280701649670

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1080/13550280701649670

Keywords

Search

Navigation